Evaluation of safety and tolerability of a rush up-dosing allergen-specific immunotherapy with grass pollen, birch, hazel, and alder allergoid in children with allergic rhinoconjunctivitis, with or without asthma.
Main Article Content
Up-dosing, Allergoid, Safety, Subcutaneous immunotherapy, Tolerability.
BACKGROUND Usually, the number of injections required to achieve the maintenance dose in subcutaneous immunotherapy (SCIT) is relatively small for some of the currently used allergens, but this may still be uncomfortable for patients, thus compromising adherence and compliance.
OBJECTIVE The purpose of this study was to evaluate the safety and tolerability of a dose acceleration of a conventional induction schedule using an allergoid extract of grass pollen, birch, hazel, and alder, needed to achieve the ideal maintenance dose.
METHODS In this open-label study, 34 patients with allergic rhinoconjunctivitis, with or without asthma, were treated with SCIT using an allergoid for grass pollen or birch or mix trees with an increase in accelerated induction dose comprising only 3 injections, one per week, compared to a conventional induction pattern in five injections (once a week). Safety determination was assessed by evaluating local and systemic adverse events. Tolerability was evaluated by patients and physicians who performed the treatment.
RESULTS No treatment-related adverse events were observed in any of the patients undergoing rush SCIT. No local reactions, no systemic reactions of any degree (WAO Grade) have been observed. Tolerability has always been rated as very good by both patients and physician.
CONCLUSIONS The induction phase, needed to achieve the monthly maintenance dose for a pollen extract, can be greatly accelerated, ensuring a tolerability comparable to that of the conventional schedule.
2. Abramson MJ, Puy RM, Weiner JM. Puy RM, Weiner JM. Injection allergen immuno‐ therapy for asthma. Cochrane Database Syst Rev. 2010;(8):Cd001186.
3. Calderon MA1, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal aller‐ gic rhinitis. Cochrane Database Syst Rev. 2007;(1):Cd001936.
4. Passalacqua G1, Baiardini I, Senna G, Canonica GW. Adherence to pharmacological treatment and specific immunotherapy in allergic rhinitis. Clin Exp Allergy. 2013;43(1):22–8.
5. Cox LS, Hankin C, Lockey R. Allergy immunotherapy adherence and delivery route: location does not matter. J Allergy Clin Immunol Pract. 2014;2(2):156–60.
6. Reisacher WR, Visaya JM. Patient adherence to allergy immunotherapy. Curr Opin Otolaryngol Head Neck Surg. 2013;21(3):256–62.
7. D. Silva, A. Pereira, N. Santos, J. L. Plácido. Costs of treatment a ect compliance to speci c subcutaneous immunotherapy. Eur Ann Allergy Clin Immunol. 2014;46(2):87–94.
8. Calabria CW. Accelerated immunotherapy schedules. Curr Allergy Asthma Rep. 2013;13(4):389–98.
9. Cox L. Advantages and disadvantages of accelerated immunotherapy schedules. J Allergy Clin Immunol. 2008;122(2):432–4.
10. Cardona R, Lopez E, Beltrán J, Sánchez J. Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra‐rush buildup. A retrospective study. Allergol Immunopathol (Madr). 2014;42(2):90–5.
11. Temiño VM, Wu P, Konig J, Fahrenholz JM. Safety of multiple aeroallergen rush immunotherapy using a modi ed schedule. Allergy Asthma Proc. 2013;34(3):255–60.
12. Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI.AAAAI and ACAAI surveillance study of subcutaneous immunotherapy, Year 3: what practices modify the risk of systemic reac‐ tions? Ann Allergy Asthma Immunol. 2013;110(4):274–278, 278.e1.
13. Maasch HJ, Marsh DG. Standardized extracts modified allergens–allergoids. Clin Rev Allergy. 1987;5(1):89–106.
14. Akdis CA, Blaser K. Regulation of specific immune responses by chemical and structural modifications of allergens. Int Arch Allergy Immunol. 2000;121(4):261–9.
15. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A; Study Group. Efficacy and safety of preseasonal‐speci c immuno‐ therapy with an aluminium‐adsorbed six‐grass pollen allergoid. Allergy. 2005;60(6):801–7.
16. Rajakulasingam K. Early improvement of patients’ condition during allergen‐speci c subcutaneous immunotherapy with a high‐dose hypoallergenic 6‐grass pollen preparation. Eur Ann Allergy Clin Immunol. 2012;44(3):128–34.
17. Brehler R, Klimek L, Pfaar O, Hauswald B, Worm M, Bieber T. Safety of a rush immunotherapy build‐up schedule with depigmented polymerized allergen extracts. Allergy Asthma Proc. 2010;31(3):e31–8.
18. Pfaar O, Urry Z, Robinson DS, Sager A, Richards D, Hawrylowicz CM, Bräutigam M, Klimek L. A randomized placebo‐controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy. Allergy. 2012;67(2):272–9.
19. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald JM, Gibson P, Ohta K, O'Byrne P, Pedersen SE, Pizzichini E, Sullivan SD, Wenzel SE, Zar HJ. Global strategy for asthma management and preven‐ tion: GINA executive summary. Eur Respir J. 2008;31(1):143–78.
20. Brehler R, Kahlert H, Thum‐Oltmer S. Hypoallergenic preparations in SCIT. Allergo J. 2010;19:477–84.
21. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: the world allergy organiza‐ tion subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol. 2010;125(3):569–574, 574.e1‐574.e7.
22. Likert R. A technique for the measurement of attitudes. Arch Psycol. 1932;22:1–55.
23. Tabar AI, Echechipía S, García BE, Olaguibel JM, Lizaso MT, Gómez B, Aldunate MT, Martin S, Marcotegui F. Double‐blind comparative study of cluster and conven‐ tional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol. 2005;116(1):109–18.
24. Linda Cox, Harold Nelson and Richard Lockey. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1–55.
25. Egert-Schmidt AM, Kolbe JM, Mussler S, Thum-Oltmer S. Patients’ compliance with different administration routes for allergen immunotherapy in Germany. Patient Prefer Adherence. 2014;8:1475–81.
26. Kiel MA, Röder E, Gerth van Wijk R, Al MJ, Hop WC, Rutten-van Mölken MP. Real‐life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol. 2013;132(2):353–360.e2.
27. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E; EAACI, Immunotherapy Task Force. Standards for practical allergen specific immunotherapy. Allergy. 2006;61(Suppl 82):1–20.